Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for XON
14.47
+1.47 (11.31%)
Real-time:   10:56AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 13.15 - 14.50
52 week 10.26 - 26.99
Open 13.19
Vol / Avg. 1.13M/1.93M
Mkt cap 1.75B
P/E     -
Div/yield     -
EPS -1.12
Shares 126.62M
Beta 1.33
Inst. own 77%
Feb 27, 2018
Q4 2017 Intrexon Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 10, 2018
Intrexon Corp at JPMorgan Healthcare Conference - Webcast
Nov 14, 2017
Intrexon Corp at Stifel Healthcare Conference - Webcast
Nov 9, 2017
Q3 2017 Intrexon Corp Earnings Call - Webcast
Nov 9, 2017
Q3 2017 Intrexon Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -88.74% -88.60%
Operating margin -97.24% -65.56%
EBITD margin - -52.69%
Return on average assets -17.88% -17.52%
Return on average equity -29.36% -29.76%
Employees 832 -
CDP Score - -

Address

1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Thomas D. Reed Ph.D. Founder, Chief Science Officer
Age: 51
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Thomas Bostick Ph.D. Chief Operating Officer
Bio & Compensation  - Reuters
Joel Liffmann Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Jack Anthony Bobo Senior Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Ena Chan Cratsenburg Senior Vice President - Consumer Sector
Age: 48
Bio & Compensation  - Reuters
Jeffrey T. Perez Senior Vice President — Intellectual Property Affairs
Age: 45
Bio & Compensation  - Reuters
Christopher Basta Vice President - Investor Relations
Bio & Compensation  - Reuters
Donald P. Lehr Chief Legal Officer
Age: 42
Bio & Compensation  - Reuters